Joan Josep Sirvent

Joan Josep Sirvent

Auto-generated profile, based on publicly available information

Joan Josep Sirvent

Department of Pathology, University Hospital Joan XXIII, Tarragona, Catalonia, Spain

Research Focus & Metrics

Academic Career Length

45Years (1982-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2010 in Toxicology
Verified
Journal Article
Closed access
MAMaria L. Albina
Maria L. Albina
VAVirginia Alonso
Virginia Alonso
VLVictoria Linares
Victoria Linares
MBMontserrat Bellés
Montserrat Bellés
JSJuan J. Sirvent
Juan J. Sirvent
DSDomènec J. Sánchez
Domènec J. Sánchez

1 January 2009 in Reproductive Toxicology
Verified
Journal Article
Closed access
VAVirginia Alonso
Virginia Alonso
VLVictoria Linares
Victoria Linares
MBMontserrat Bellés
Montserrat Bellés
MAMaria L. Albina
Maria L. Albina
JSJuan J. Sirvent
Juan J. Sirvent
DSDomènec J. Sánchez
Domènec J. Sánchez

1 December 2006 in Toxicology Letters
Verified
Journal Article
Closed access
VLVictoria Linares
Victoria Linares
MBMontserrat Bellés
Montserrat Bellés
MAM. Luisa Albina
M. Luisa Albina
JSJuan J. Sirvent
Juan J. Sirvent
DSDomènec J. Sánchez
Domènec J. Sánchez
Jose L DomingoJose L Domingo
Jose L Domingo

Verified
Journal Article
Open access
PDF file
TATeresa Auguet
Teresa Auguet
ABAlba Berlanga
Alba Berlanga
EJEsther Guiu Jurado
Esther Guiu Jurado
SMSALOME MARTINEZ
SALOME MARTINEZ
JPJosé Antonio Porras
José Antonio Porras
CRCristóbal Richart
Cristóbal Richart
Lipid accumulation in the human liver seems to be a crucial mechanism in the pathogenesis and the progression of non-alcoholic fatty liver disease (NAFLD). We aimed to evaluate gene expression of different fatty acid (FA) metabolism-related genes in morbidly obese (MO) women with NAFLD. Liver expression of key genes related to de novo FA synthesis (LXRα, SREBP1c, ACC1, FAS), FA uptake and transport (PPARγ, CD36, FABP4), FA oxidation (PPARα), and inflammation (IL6, TNFα, CRP, PPARδ) were assessed by RT-qPCR in 127 MO women with normal liver histology (NL, n = 13), simple steatosis (SS, n = 47) and non-alcoholic steatohepatitis (NASH, n = 67). Liver FAS mRNA expression was significantly higher in MO NAFLD women with both SS and NASH compared to those with NL (p = 0.003, p = 0.010, respectively). Hepatic IL6 and TNFα mRNA expression was higher in NASH than in SS subjects (p = 0.033, p = 0.050, respectively). Interestingly, LXRα, ACC1 and FAS expression had an inverse relation with the grade of steatosis. These results were confirmed by western blot analysis. In conclusion, our results indicate that lipogenesis seems to be downregulated in advanced stages of SS, suggesting that, in this type of extreme obesity, the deregulation of the lipogenic pathway might be associated with the severity of steatosis.

1 April 2016 in Reproductive Toxicology
Verified
Journal Article
Closed access
DLD. Lafuente
D. Lafuente
TGT. Garcia
T. Garcia
JBJordi Blanco
Jordi Blanco
DSD.J. Sánchez
D.J. Sánchez
JSJ.J. Sirvent
J.J. Sirvent
MGM. Gómez
M. Gómez

Verified
Journal Article
Open access
PDF file
TATeresa Auguet
Teresa Auguet
GAGemma Aragonès
Gemma Aragonès
ABAlba Berlanga
Alba Berlanga
EJEsther Guiu Jurado
Esther Guiu Jurado
AMAndreu Martí
Andreu Martí
CRCristóbal Richart
Cristóbal Richart
Specific miRNA expression profiles have been shown to be associated with nonalcoholic fatty liver disease (NAFLD). We examined the correlation between the circulating levels and hepatic expression of miR122 and miR33a/b*, the key lipid metabolism-related gene expression and the clinicopathological factors of obese women with NAFLD. We measured miR122 and miR33a/b* expression in liver samples from 62 morbidly obese (MO), 30 moderately obese (ModO), and eight normal-weight controls. MiR122 and miR33a/b* expression was analyzed by qRT-PCR. Additionally, miR122 and miR33b* circulating levels were analyzed in 122 women. Hepatic miR33b* expression was increased in MO compared to ModO and controls, whereas miR122 expression was decreased in the MO group compared to ModO. In obese cohorts, miR33b* expression was increased in nonalcoholic steatohepatitis (NASH). Regarding circulating levels, MO patients with NASH showed higher miR122 levels than MO with simple steatosis (SS). These circulating levels are good predictors of histological features associated with disease severity. MO is associated with altered hepatic miRNA expression. In obese women, higher miR33b* liver expression is associated with NASH. Moreover, multiple correlations between miRNAs and the expression of genes related to lipid metabolism were found, that would suggest a miRNA-host gene circuit. Finally, miR122 circulating levels could be included in a panel of different biomarkers to improve accuracy in the non-invasive diagnosis of NASH.